Hinge Health (HNGE) drew fresh investor attention on 4 August 2026 after reporting second quarter earnings, raising full year guidance, updating its share buyback activity, and outlining expansion plans in digital gastrointestinal care.

The latest results and acquisition news came on top of strong recent momentum in Hinge Health's stock, with a 1 day share price return of 11.55%, a 7 day share price return of 19.57% and a 90 day share price return of 59.46%, while the 1 year total shareholder return is 57.60%. This suggests enthusiasm has been building rather than fading.

If this kind of move has your attention, it can be helpful to see what else is gaining traction in related areas by scanning 43 healthcare AI stocks.

Bullish investors see Hinge Health as a profitable growth story that the market still discounts. Sceptics worry the recent surge already prices in the good news. Which side do the current valuation markers support?

Most Popular Narrative: 1.7% Undervalued

On the latest figures, Hinge Health closed at $89.33, while the most followed narrative points to a fair value of $90.87 using a 7.11% discount rate.

Expansion of integrated digital and in person offerings through HingeSelect and broader provider network build out positions the company to pursue a larger share of MSK and adjacent care pathways, potentially increasing lives under contract and long term revenue per client.

Want to see why this narrative leans into strong top line growth, rising margins and a rich future earnings multiple? The key assumptions are bolder than headlines suggest.

Result: Fair Value of $90.87 (UNDERVALUED)

However, Hinge Health still faces two clear swing factors: employer or health plan budget cuts could slow digital MSK adoption, and any AI related regulatory issues could weigh on margins.

Another View: What Hinge Health’s P/E Is Telling You

While the SWS fair value of $90.87 frames Hinge Health as 52.2% undervalued on future cash flows, the P/E picture is less forgiving. The stock trades on 64.4x earnings versus a fair ratio of 43.8x and a US Healthcare average of 25.4x. That is a rich entry price if the narrative cools.

On the other hand, Hinge Health is roughly in line with its peer average P/E of 64.5x. This suggests the market is already pricing it as a premium growth story rather than an outlier. The real question is whether you think earnings will grow fast enough for that high multiple to feel comfortable a few years from now.

Next Steps

With sentiment running hot around Hinge Health, it helps to move past headlines and review the underlying rewards that investors are focused on. You can review the full breakdown of 3 key rewards

Looking for more investment ideas beyond Hinge Health?

If Hinge Health has sharpened your focus, do not stop here. Broaden your watchlist with a few focused stock ideas sourced directly from Simply Wall Street screeners.

• Target quality at a discount by scanning 51 high quality undervalued stocks that already combine robust cash flows with solid balance sheets.
• Strengthen your income stream by reviewing 8 dividend fortresses that aim to pair higher yields with resilience.
• Reduce portfolio stress by checking 79 resilient stocks with low risk scores that score well on stability metrics before the wider market catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.